meloxicam Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
anti-inflammatory, isoxicam derivatives 1676 71125-38-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • reumoxicam
  • miloxicam
  • meloxicam
  • metacam
  • meloxicam sodium
  • meloxicam sodium hydrate
Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic, and antipyretic activities in animal models. The mechanism of action of meloxicam, like that of other NSAIDs, may be related to prostaglandin synthetase (cyclo-oxygenase) inhibition.
  • Molecular weight: 351.40
  • Formula: C14H13N3O4S2
  • CLOGP: 2.29
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 2
  • TPSA: 99.60
  • ALOGS: -3.36
  • ROTB: 2

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
15 mg O
15 mg P
15 mg R

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.01 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.20 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.71 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 97 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.15 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.12 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.00 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 18 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
April 13, 2000 FDA BOEHRINGER INGELHEIM

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug hypersensitivity 1095.93 31.66 350 1920 46293 2309522
Completed suicide 550.25 31.66 173 2097 20861 2334954
Drug ineffective 400.20 31.66 214 2056 101410 2254405
Toxicity to various agents 239.21 31.66 106 2164 32648 2323167
Gastrointestinal haemorrhage 233.50 31.66 80 2190 12355 2343460
Acute kidney injury 192.23 31.66 87 2183 28035 2327780
Synovial fluid analysis 184.24 31.66 24 2246 7 2355808
Arthralgia 174.85 31.66 101 2169 54184 2301631
Gastric ulcer 158.90 31.66 43 2227 2973 2352842
Fibromyalgia 155.07 31.66 43 2227 3257 2352558
Synovial cyst 153.98 31.66 33 2237 837 2354978
Rheumatoid arthritis 152.42 31.66 66 2204 19074 2336741
Tenosynovitis stenosans 148.94 31.66 24 2246 111 2355704
Musculoskeletal stiffness 148.07 31.66 57 2213 12190 2343625
Joint swelling 137.14 31.66 59 2211 16760 2339055
Scleritis 129.17 31.66 24 2246 284 2355531
Pain 127.96 31.66 87 2183 61770 2294045
Nausea 126.90 31.66 110 2160 112079 2243736
Impaired work ability 125.00 31.66 32 2238 1778 2354037
Rheumatoid nodule 123.96 31.66 26 2244 592 2355223
Crepitations 122.02 31.66 26 2244 640 2355175
Dry eye 121.26 31.66 37 2233 3919 2351896
Ulcer 118.95 31.66 31 2239 1849 2353966
Musculoskeletal pain 118.80 31.66 47 2223 10783 2345032
Abdominal pain 118.45 31.66 67 2203 34307 2321508
Pain in extremity 115.35 31.66 71 2199 42469 2313346
Cushingoid 112.81 31.66 24 2246 586 2355229
Pleuritic pain 111.25 31.66 24 2246 627 2355188
Antinuclear antibody positive 109.46 31.66 26 2244 1056 2354759
Cardio-respiratory arrest 108.42 31.66 42 2228 9104 2346711
Anaemia 107.01 31.66 63 2207 34729 2321086
Bursitis 104.18 31.66 28 2242 1880 2353935
Peripheral swelling 102.95 31.66 49 2221 17548 2338267
Flank pain 100.26 31.66 26 2244 1519 2354296
Joint effusion 100.17 31.66 25 2245 1251 2354564
Anaphylactic reaction 99.05 31.66 40 2230 9665 2346150
Drug intolerance 98.35 31.66 44 2226 13673 2342142
Cardiac arrest 97.91 31.66 45 2225 14885 2340930
Pruritus 96.70 31.66 64 2206 43276 2312539
Interstitial lung disease 96.59 31.66 37 2233 7775 2348040
Tenderness 94.68 31.66 26 2244 1892 2353923
Photophobia 94.61 31.66 27 2243 2262 2353553
Dizziness 94.61 31.66 71 2199 58594 2297221
Gastric ulcer haemorrhage 94.48 31.66 22 2248 818 2354997
Conjunctivitis 93.43 31.66 27 2243 2366 2353449
Nodule 90.85 31.66 26 2244 2200 2353615
Feeling jittery 89.89 31.66 25 2245 1907 2353908
Atelectasis 89.47 31.66 25 2245 1940 2353875
Rash 89.23 31.66 69 2201 59489 2296326
Ocular hyperaemia 87.33 31.66 29 2241 4027 2351788
Drug interaction 84.86 31.66 51 2219 29112 2326703
Linear IgA disease 83.26 31.66 17 2253 337 2355478
Melaena 83.01 31.66 28 2242 4078 2351737
Renal failure 82.60 31.66 42 2228 17307 2338508
Therapeutic product effect decreased 81.78 31.66 36 2234 10753 2345062
Tubulointerstitial nephritis 79.80 31.66 24 2246 2414 2353401
Eye irritation 79.17 31.66 26 2244 3486 2352329
Diarrhoea 78.42 31.66 74 2196 83490 2272325
Wheezing 78.04 31.66 30 2240 6354 2349461
Dry mouth 77.29 31.66 32 2238 8221 2347594
Colitis microscopic 76.77 31.66 19 2251 917 2354898
Abdominal discomfort 76.58 31.66 40 2230 17416 2338399
Malaise 75.87 31.66 61 2209 55524 2300291
Lung disorder 75.25 31.66 29 2241 6183 2349632
Haemoglobin decreased 75.11 31.66 40 2230 18111 2337704
Dyspnoea 74.37 31.66 70 2200 78663 2277152
Renal impairment 74.30 31.66 33 2237 10059 2345756
Duodenal ulcer 73.17 31.66 19 2251 1114 2354701
Swelling face 72.98 31.66 32 2238 9461 2346354
Vomiting 70.17 31.66 65 2205 71537 2284278
Tinnitus 69.50 31.66 26 2244 5109 2350706
Gastritis 68.65 31.66 25 2245 4556 2351259
Arthritis 68.29 31.66 31 2239 9937 2345878
Haematemesis 67.65 31.66 24 2246 4058 2351757
Eye pain 67.05 31.66 25 2245 4866 2350949
Visual impairment 66.43 31.66 32 2238 11723 2344092
Faeces discoloured 63.54 31.66 20 2250 2339 2353476
Erythema 62.96 31.66 40 2230 25119 2330696
Neoplasm malignant 62.47 31.66 24 2246 5069 2350746
Purpura senile 62.17 31.66 9 2261 16 2355799
Fixed eruption 62.16 31.66 12 2258 176 2355639
Tenosynovitis 60.59 31.66 14 2256 502 2355313
Abdominal pain upper 59.98 31.66 37 2233 22063 2333752
Hyperkalaemia 59.07 31.66 24 2246 5869 2349946
Pneumonia 58.64 31.66 50 2220 49246 2306569
Focal segmental glomerulosclerosis 58.33 31.66 12 2258 247 2355568
Respiratory arrest 57.97 31.66 24 2246 6154 2349661
Hypertension 57.49 31.66 39 2231 27322 2328493
Haemorrhage 56.23 31.66 28 2242 11011 2344804
Thrombosis 55.02 31.66 26 2244 9118 2346697
Condition aggravated 54.26 31.66 40 2230 31939 2323876
Toxic epidermal necrolysis 54.04 31.66 19 2251 3125 2352690
Rectal haemorrhage 52.42 31.66 22 2248 5834 2349981
Tarsal tunnel syndrome 49.98 31.66 8 2262 35 2355780
Treatment failure 47.94 31.66 22 2248 7217 2348598
Fatigue 47.15 31.66 57 2213 84816 2270999
Drug reaction with eosinophilia and systemic symptoms 46.96 31.66 20 2250 5498 2350317
Lymphomatoid papulosis 46.68 31.66 8 2262 57 2355758
Infection 45.90 31.66 29 2241 18000 2337815
Nodular rash 45.75 31.66 8 2262 65 2355750
Muscular weakness 45.70 31.66 27 2243 14870 2340945
Osteoarthritis 45.65 31.66 21 2249 6925 2348890
Upper gastrointestinal haemorrhage 45.29 31.66 15 2255 2059 2353756
Hypotension 44.98 31.66 36 2234 32400 2323415
Dehydration 42.61 31.66 30 2240 22265 2333550
Pulmonary toxicity 41.81 31.66 11 2259 678 2355137
Headache 41.52 31.66 52 2218 80127 2275688
Somnolence 41.21 31.66 30 2240 23455 2332360
Asthenia 40.87 31.66 40 2230 46886 2308929
Contraindicated product administered 39.78 31.66 15 2255 3006 2352809
Myalgia 39.11 31.66 29 2241 23304 2332511
Metabolic acidosis 38.99 31.66 18 2252 5980 2349835
Crystal nephropathy 38.82 31.66 7 2263 69 2355746
Suicide attempt 38.71 31.66 22 2248 11260 2344555
Chest pain 38.51 31.66 31 2239 28106 2327709
Lethargy 38.21 31.66 20 2250 8710 2347105
Pyrexia 38.11 31.66 41 2229 53667 2302148
Diverticulum 37.58 31.66 12 2258 1467 2354348
Blood creatinine increased 37.38 31.66 21 2249 10512 2345303
Hiatus hernia 37.36 31.66 13 2257 2071 2353744
Vestibular disorder 36.59 31.66 8 2262 222 2355593
Resorption bone increased 36.19 31.66 8 2262 234 2355581
Gastric ulcer perforation 35.99 31.66 8 2262 240 2355575
Acute respiratory distress syndrome 35.02 31.66 14 2256 3278 2352537
Gastrointestinal disorder 35.00 31.66 19 2251 8898 2346917
Joint range of motion decreased 34.91 31.66 12 2258 1844 2353971
Therapeutic product effect incomplete 34.69 31.66 20 2250 10511 2345304
Overdose 33.93 31.66 25 2245 19882 2335933
Intentional product misuse 33.89 31.66 19 2251 9470 2346345
Confusional state 33.68 31.66 27 2243 24317 2331498
Loss of consciousness 32.96 31.66 24 2246 18743 2337072
Therapeutic response unexpected 32.87 31.66 14 2256 3845 2351970
Rheumatoid lung 32.64 31.66 7 2263 177 2355638
Rash pruritic 32.22 31.66 17 2253 7518 2348297
Duodenal ulcer haemorrhage 31.91 31.66 8 2262 406 2355409
Gastrooesophageal reflux disease 31.91 31.66 18 2252 9077 2346738
Fall 31.72 31.66 35 2235 47064 2308751

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Completed suicide 223.42 34.26 80 1129 16232 1729340
Gastrointestinal haemorrhage 214.40 34.26 75 1134 14192 1731380
Drug hypersensitivity 202.47 34.26 73 1136 15062 1730510
Gastric haemorrhage 189.77 34.26 48 1161 2930 1742642
Toxicity to various agents 175.19 34.26 79 1130 29062 1716510
Duodenal ulcer 150.67 34.26 36 1173 1724 1743848
Melaena 103.83 34.26 34 1175 5176 1740396
Gastric ulcer 98.38 34.26 28 1181 2657 1742915
Acute kidney injury 90.55 34.26 54 1155 34890 1710682
Duodenal ulcer haemorrhage 88.15 34.26 20 1189 757 1744815
Drug ineffective 73.73 34.26 60 1149 63741 1681831
Upper gastrointestinal haemorrhage 69.61 34.26 22 1187 2977 1742595
Anaemia 67.12 34.26 42 1167 29415 1716157
Electrocardiogram QRS complex prolonged 61.83 34.26 15 1194 760 1744812
Drug interaction 61.50 34.26 39 1170 27919 1717653
Acute generalised exanthematous pustulosis 61.10 34.26 16 1193 1106 1744466
Cardio-respiratory arrest 57.91 34.26 26 1183 9267 1736305
Intestinal diaphragm disease 54.74 34.26 9 1200 56 1745516
Dizziness 54.18 34.26 39 1170 34322 1711250
Haemoglobin decreased 53.56 34.26 30 1179 17084 1728488
Overdose 51.51 34.26 29 1180 16672 1728900
Coma 47.40 34.26 21 1188 7241 1738331
Haemorrhage 47.27 34.26 23 1186 9806 1735766
Unresponsive to stimuli 45.75 34.26 18 1191 4611 1740961
Fixed eruption 43.11 34.26 9 1200 228 1745344
Cardiotoxicity 41.21 34.26 11 1198 817 1744755
Haematocrit decreased 40.07 34.26 16 1193 4257 1741315
Respiratory failure 38.86 34.26 23 1186 14482 1731090
Intestinal perforation 38.04 34.26 12 1197 1607 1743965
Gastritis 37.52 34.26 14 1195 3103 1742469
Ileus 36.97 34.26 13 1196 2433 1743139
Haematemesis 36.27 34.26 15 1194 4362 1741210
Atrial fibrillation 35.42 34.26 22 1187 15089 1730483
Gastric ulcer haemorrhage 34.66 34.26 10 1199 989 1744583

Pharmacologic Action:

SourceCodeDescription
ATC M01AC06 MUSCULO-SKELETAL SYSTEM
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
Oxicams
ATC M01AC56 MUSCULO-SKELETAL SYSTEM
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
Oxicams
FDA EPC N0000175722 Nonsteroidal Anti-inflammatory Drug
FDA Chemical/Ingredient N0000175721 Nonsteroidal Anti-inflammatory Compounds
MeSH PA D000700 Analgesics
MeSH PA D018712 Analgesics, Non-Narcotic
MeSH PA D000893 Anti-Inflammatory Agents
MeSH PA D000894 Anti-Inflammatory Agents, Non-Steroidal
MeSH PA D018501 Antirheumatic Agents
MeSH PA D052246 Cyclooxygenase 2 Inhibitors
MeSH PA D016861 Cyclooxygenase Inhibitors
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D018689 Sensory System Agents
CHEBI has role CHEBI:35475 non-steroidal anti-inflammatory drug
CHEBI has role CHEBI:35842 antirheumatic drug
CHEBI has role CHEBI:35480 analgesic

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Rheumatoid arthritis indication 69896004 DOID:7148
Osteoarthritis indication 396275006
Juvenile rheumatoid arthritis indication 410795001
Ankylosing spondylitis off-label use 9631008 DOID:7147
Gastritis contraindication 4556007 DOID:4029
Alcoholism contraindication 7200002
Myocardial infarction contraindication 22298006 DOID:5844
Hypertensive disorder contraindication 38341003 DOID:10763
Gastrointestinal ulcer contraindication 40845000
Body fluid retention contraindication 43498006
Chronic heart failure contraindication 48447003
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Gastrointestinal perforation contraindication 51875005
Hyperlipidemia contraindication 55822004 DOID:1168
Blood coagulation disorder contraindication 64779008 DOID:1247
Aortocoronary artery bypass graft contraindication 67166004
Diabetes mellitus contraindication 73211009 DOID:9351
Gastrointestinal hemorrhage contraindication 74474003
Kidney disease contraindication 90708001 DOID:557
Liver function tests abnormal contraindication 166603001
Impaired renal function disorder contraindication 197663003
Cerebrovascular accident contraindication 230690007
Coronary artery bypass graft contraindication 232717009
Edema contraindication 267038008
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thromboembolic disorder contraindication 371039008
Cardiovascular event risk contraindication 395112001
Smokes tobacco daily contraindication 449868002

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.65 acidic
pKa2 5.42 acidic
pKa3 4.32 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
30MG/ML (30MG/ML) ANJESO BAUDAX N210583 Feb. 20, 2020 RX SOLUTION INTRAVENOUS 8512727 Dec. 25, 2022 MANAGEMENT OF MODERATE-TO-SEVERE PAIN BY INTRAVENOUS INJECTION
30MG/ML (30MG/ML) ANJESO BAUDAX N210583 Feb. 20, 2020 RX SOLUTION INTRAVENOUS 10463673 Feb. 24, 2024 MANAGEMENT OF MODERATE-TO-SEVERE PAIN BY INTRAVENOUS INJECTION
30MG/ML (30MG/ML) ANJESO BAUDAX N210583 Feb. 20, 2020 RX SOLUTION INTRAVENOUS 10471067 Feb. 24, 2024 MANAGEMENT OF MODERATE-TO-SEVERE PAIN BY INTRAVENOUS INJECTION
10MG VIVLODEX ZYLA N207233 Oct. 22, 2015 RX CAPSULE ORAL 9808468 March 31, 2035 MANAGEMENT OF OSTEOARTHRITIS PAIN BY ADMINISTERING 10 MG OF MELOXICAM
10MG VIVLODEX ZYLA N207233 Oct. 22, 2015 RX CAPSULE ORAL 9808468 March 31, 2035 MANAGEMENT OF OSTEOARTHRITIS PAIN BY ADMINISTERING 5 MG OF MELOXICAM
5MG VIVLODEX ZYLA N207233 Oct. 22, 2015 RX CAPSULE ORAL 9808468 March 31, 2035 MANAGEMENT OF OSTEOARTHRITIS PAIN BY ADMINISTERING 10 MG OF MELOXICAM
5MG VIVLODEX ZYLA N207233 Oct. 22, 2015 RX CAPSULE ORAL 9808468 March 31, 2035 MANAGEMENT OF OSTEOARTHRITIS PAIN BY ADMINISTERING 5 MG OF MELOXICAM

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
30MG/ML (30MG/ML) ANJESO BAUDAX N210583 Feb. 20, 2020 RX SOLUTION INTRAVENOUS Feb. 20, 2023 NEW PRODUCT

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Prostaglandin G/H synthase 2 Enzyme INHIBITOR IC50 6.80 CHEMBL CHEMBL
Prostaglandin G/H synthase 1 Enzyme IC50 5.85 CHEMBL

External reference:

IDSource
D000077239 MESH_DESCRIPTOR_UI
4021203 VUID
N0000148649 NUI
C0083381 UMLSCUI
D00969 KEGG_DRUG
125694008 SNOMEDCT_US
4021203 VANDF
84146 MMSL
006272 NDDF
d04532 MMSL
8839 MMSL
41493 RXNORM
387055000 SNOMEDCT_US
CHEMBL599 ChEMBL_ID
DB00814 DRUGBANK_ID
VG2QF83CGL UNII
5615 INN_ID
MXM PDB_CHEM_ID
CHEBI:6741 CHEBI
CHEMBL1256873 ChEMBL_ID
54677470 PUBCHEM_CID
7220 IUPHAR_LIGAND_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
meloxicam HUMAN PRESCRIPTION DRUG LABEL 1 0179-0179 TABLET 7.50 mg ORAL ANDA 19 sections
meloxicam HUMAN PRESCRIPTION DRUG LABEL 1 0179-0180 TABLET 15 mg ORAL ANDA 19 sections
Meloxicam HUMAN PRESCRIPTION DRUG LABEL 1 0440-5841 TABLET 7.50 mg ORAL ANDA 18 sections
Mobic HUMAN PRESCRIPTION DRUG LABEL 1 0597-0029 TABLET 7.50 mg ORAL NDA 19 sections
Mobic HUMAN PRESCRIPTION DRUG LABEL 1 0597-0030 TABLET 15 mg ORAL NDA 19 sections
Meloxicam HUMAN PRESCRIPTION DRUG LABEL 1 0615-6568 TABLET 7.50 mg ORAL ANDA 18 sections
Meloxicam HUMAN PRESCRIPTION DRUG LABEL 1 0615-6569 TABLET 15 mg ORAL ANDA 18 sections
Meloxicam HUMAN PRESCRIPTION DRUG LABEL 1 0615-7885 TABLET 7.50 mg ORAL ANDA 20 sections
meloxicam HUMAN PRESCRIPTION DRUG LABEL 1 0615-7886 TABLET 15 mg ORAL ANDA 20 sections
MELOXICAM HUMAN PRESCRIPTION DRUG LABEL 1 0615-8040 TABLET 7.50 mg ORAL ANDA 19 sections
MELOXICAM HUMAN PRESCRIPTION DRUG LABEL 1 0615-8124 TABLET 15 mg ORAL ANDA 19 sections
Meloxicam HUMAN PRESCRIPTION DRUG LABEL 1 10544-052 TABLET 15 mg ORAL ANDA 18 sections
Meloxicam HUMAN PRESCRIPTION DRUG LABEL 1 10544-090 TABLET 7.50 mg ORAL ANDA 18 sections
Meloxicam HUMAN PRESCRIPTION DRUG LABEL 1 10544-251 TABLET 15 mg ORAL ANDA 17 sections
Meloxicam HUMAN PRESCRIPTION DRUG LABEL 1 10544-252 TABLET 7.50 mg ORAL ANDA 17 sections
meloxicam HUMAN PRESCRIPTION DRUG LABEL 1 10544-555 TABLET 15 mg ORAL ANDA 19 sections
meloxicam HUMAN PRESCRIPTION DRUG LABEL 1 10544-631 TABLET 7.50 mg ORAL ANDA 19 sections
meloxicam HUMAN PRESCRIPTION DRUG LABEL 1 10544-925 TABLET 15 mg ORAL ANDA 18 sections
MELOXICAM HUMAN PRESCRIPTION DRUG LABEL 1 16590-434 TABLET 7.50 mg ORAL ANDA 18 sections
MELOXICAM HUMAN PRESCRIPTION DRUG LABEL 1 16590-469 TABLET 15 mg ORAL ANDA 18 sections
Meloxicam HUMAN PRESCRIPTION DRUG LABEL 1 21695-076 TABLET 7.50 mg None ANDA 14 sections
Meloxicam HUMAN PRESCRIPTION DRUG LABEL 1 21695-077 TABLET 15 mg ORAL ANDA 14 sections
meloxicam HUMAN PRESCRIPTION DRUG LABEL 1 29300-124 TABLET 7.50 mg ORAL ANDA 19 sections
meloxicam HUMAN PRESCRIPTION DRUG LABEL 1 29300-125 TABLET 15 mg ORAL ANDA 19 sections
meloxicam HUMAN PRESCRIPTION DRUG LABEL 1 33261-070 TABLET 7.50 mg ORAL ANDA 19 sections
meloxicam HUMAN PRESCRIPTION DRUG LABEL 1 33261-071 TABLET 15 mg ORAL ANDA 19 sections
meloxicam HUMAN PRESCRIPTION DRUG LABEL 1 35356-808 TABLET 7.50 mg ORAL ANDA 18 sections
Vivlodex HUMAN PRESCRIPTION DRUG LABEL 1 42211-205 CAPSULE 5 mg ORAL NDA 19 sections
Vivlodex HUMAN PRESCRIPTION DRUG LABEL 1 42211-206 CAPSULE 10 mg ORAL NDA 19 sections
Meloxicam HUMAN PRESCRIPTION DRUG LABEL 1 42549-519 TABLET 15 mg ORAL ANDA 14 sections